Gain insights into the operational challenges facing clinical research sites today, learn what sponsors and CROs can do to ...
Strong relational governance between technology vendors and sponsor–CRO teams is becoming a critical foundation for eCOA ...
In today’s ACT Brief, we look at how AI and in-silico methods are reshaping drug repurposing, why staggered ICH GCP rollouts ...
ACT: As new ICH GCP guidelines roll out, how are sponsors balancing the drive for innovation—especially in areas like CAR-T ...
For industry-sponsored trials in autoimmune inflammation therapeutic areas, the dominating indications include atopic ...
The FDA has launched a secure, GovCloud-based agentic AI system to support regulatory workflows across review divisions, ...
In today’s ACT Brief, we look at what’s fueling rapid growth in CNS and autoimmune research, why former FDA leaders are ...
Chen: Yes, obesity is experiencing accelerated growth over the last couple of years. According to our sister product Evaluate ...
In today’s ACT Brief, we look at new insights on strategy-driven clinical development, fresh survey data revealing persistent ...
In today’s ACT Brief, we examine how the FDA’s CNPV Program is reshaping operational planning and accelerated submission ...
Examine the rise of personalized and biomarker-driven therapies, the logistical challenges of rare patient populations, and ...
Former FDA Commissioners Warn New Vaccine Policies Could Undermine Longstanding Regulatory Framework
In their NEJM commentary, the former FDA heads stated, “We are deeply concerned by sweeping new FDA assertions about vaccine safety and proposals that would undermine a regulatory model designed to ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback